Modality
Gene Editing
MOA
CAR-T BCMA
Target
EZH2
Pathway
Angiogenesis
Wilms
Development Pipeline
Preclinical
~Sep 2018
→ ~Dec 2019
Phase 1
~Mar 2020
→ ~Jun 2021
Phase 2
~Sep 2021
→ ~Dec 2022
Phase 3
~Mar 2023
→ ~Jun 2024
NDA/BLA
Sep 2024
→ Nov 2027
NDA/BLACurrent
NCT03196395
287 pts·Wilms
2024-09→2027-11·Recruiting
287 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-11-081.6y awayPh3 Readout· Wilms
Trial Timeline
Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2027-11-08 · 1.6y away
Wilms
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03196395 | NDA/BLA | Wilms | Recruiting | 287 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn | |
| ACA-2691 | Acadia Pharma | Phase 3 | BCMA | |
| Olpasotorasib | Structure Ther | Preclinical | C5 | |
| AGI-4446 | Agios | Phase 3 | PSMA |